{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-021318","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.901544+00:00","generated_at":"2026-06-14T05:37:24.037458+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cumberland Pharmaceuticals receives FDA waiver, $1.2M refund for RediTrex fees","bullets":["FDA granted barrier-to-innovation waiver based on ifetroban clinical programs addressing unmet medical needs.","Company will receive refund of approximately $1.2 million in prescription drug program fees for RediTrex.","Refund expected within 45 days from FDA's Office of Financial Management.","Waiver follows Cumberland's April 3, 2023 request for reconsideration through counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-021318","json":"https://secwatch.observer/filing/0001628280-23-021318.json","markdown":"https://secwatch.observer/filing/0001628280-23-021318.md","text":"https://secwatch.observer/filing/0001628280-23-021318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023021318/0001628280-23-021318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023021318/cpix-20230602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:37:24.037458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}